Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder

NCT06672705 is registered in ClinicalTrials.gov with Timothy Voorhees as lead sponsor.

NCT NCT06672705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06672705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder
Lead sponsor
Timothy Voorhees
Phase
Phase 1
Overall status
Recruiting
Start date
June 16, 2025
Completion date
December 31, 2026
Enrollment
26 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma post-transplant lymphoproliferative disorder, ebv-related post-transplant lymphoproliferative disorder, recurrent monomorphic post-transplant lymphoproliferative disorder, recurrent polymorphic post-transplant lymphoproliferative disorder, refractory monomorphic post-transplant lymphoproliferative disorder, refractory polymorphic post-transplant lymphoproliferative disorder